Tag Archives: drug cost
Biotech drugs: Pushing policy boundaries
Since the passage of the Medicare prescription drug benefit (Part D), Medicare policy and pricing decisions have taken on a role normally assigned to the market: the ongoing challenge to balance access considerations, the role and strength of evidence for efficacy and safety, and the cost of new treatments. Biotech medicines are under the spotlight for a number of reasons. Continue reading
“Do something!” How increased prescription drug utilization may lead to price controls
I don’t know what the answer is. As I’ve said, I believe that healthcare is a public good and cannot be treated as a consumer item. “Can’t afford a Lexus? How ’bout that Kia?” It doesn’t–and shouldn’t–work that way for healthcare. However, healthcare does respond to price like a consumer good. Continue reading
Filed under Pharmaceutical legislation
